Metabolic risks remain largely unmonitored in Medicaid patients taking antipsychotics
Despite government warnings and professional recommendations about diabetes risks associated with second-generation antipsychotic drugs, fewer than one-third of Medicaid patients who are treated with these medications undergo ...
